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Summary
INTRODUCTION: In 2009 hypovitaminosis D was highly
prevalent in a population of Swiss rheumatology patients
(86%). We aimed to evaluate the evolution of vitamin D
status in the same population two years later, after the res-
ults of the first study were disseminated to local physi-
cians and patients, in order to determine the evolution of
the problem and the impact of physician information.
METHOD: Patients in our rheumatology clinic were
screened for 25-OH vitamin D. Results were categorised
as: deficient (<10 ng/ml or <25 nmol/l), insufficient (10 to
30 ng/ml or 25 to 75 nmol/l) or normal (>30 ng/ml or >75
nmol/l). We also used another cut-off of 20 ng/ml (50 nmol/
l). We evaluated the evolution of 25-OH vitamin D dosages
and vitamin D3 prescriptions between 2008 and 2011 in
our institution and the number of publications on vitamin D
in three important medical journals of the French speaking
part of Switzerland.
RESULTS: Compared with 2009, significantly more pa-
tients had normal results in 2011. Fifty-two percent of pa-
tients had levels >20 ng/ml in 2009 and 66% in 2011,
difference statistically significant (p = 0.001). During the
years separating the two study periods the number of
25-OH vitamin D dosages and the prescription of high
doses of vitamin D3 increased in our hospital. In addition
the number of publications on vitamin D increased between
2008 and 2011.
CONCLUSION: We concluded that lower prevalence in
hypovitaminosis D is certainly related to better adherence
to daily supplements, and to better information and aware-
ness of the physicians about hypovitaminosis D.
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Introduction
Vitamin D is an important factor for bone metabolism and
neuromuscular function [1]. Vitamin D supplementation is
effective in lowering the risk of fall and fracture in eld-
erly subjects [2, 3]. Some experts recommend a level high-
er than 30 ng/ml (75 nmol/l) for high-risk patients [4–6].
There is an overall consensus among scientific organisa-
tions that levels higher than 20 ng/ml (50 nmol/l) are ne-
cessary for bone and muscular health [7–9]. Old and recent
studies have already shown a high prevalence of hypovit-
aminosis D in Switzerland [10, 11], and a few studies have
also underlined this problem among rheumatology outpa-
tients [12, 13]. We have shown that hypovitaminosis D
was highly prevalent in an outpatient population of Swiss
rheumatology patients, affecting 86% of subjects in 2009
[14]. This situation could be explained by different causes:
lack of sufficient sunshine, sun avoidance in older patients
or patients with photosensitivity, inadequate clinician and
patient information, infrequent screening and suboptimal
adherence to daily substitution or insufficient supplement-
ation. Therefore we aimed to evaluate the evolution of vit-
amin D status in the same outpatient rheumatology pop-
ulation two years later, after the results of the first study
were widely disseminated to local physicians and patients,
to determine the evolution of the problem and the impact of
physician information.
Method
We evaluated the prevalence of hypovitaminosis D in an
outpatient population attending the rheumatology clinic of
the University Hospital of Lausanne in November 2009
[14]. Between November 2009 and October 2011, we in-
formed and sensitised local physicians about the risks and
the management of hypovitaminosis D and presented res-
ults of this first study. Next, we repeated the same screen-
ing in November 2011. All patients in our rheumatology
clinic were offered a screening test for 25-OH vitamin D.
The results were categorised as: deficient (<10 ng/ml or
<25 nmol/l), insufficient (10 to 30 ng/ml or 25 to 75 nmol/
l) or normal (>30 ng/ml or >75 nmol/l). We also used the
more recently recommended cut-off of 20 ng/ml (50 nmol/
l) and revaluate the 2011 and 2009 populations with it.
Vitamin D levels were determined using radioimmunolo-
gical assay with extraction (25-hydroxyvitamin D 125I RIA
Kit, DiaSorin®).
Patients were asked about their calcium and vitamin D
supplementation. We compared the results with those of
November 2009 after exclusion of patients who were not
regularly followed in our clinic and those who received a
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high dose (300,000 IU) of oral or intramuscular vitamin D
in the previous six months in both screening populations.
We asked the central laboratory and pharmacy of our uni-
versity hospital about the evolution of 25-OH vitamin D
dosages and vitamin D3 prescriptions between 2008 and
2011. Finally, to try and determine the impact of local
physician education, we evaluated the number of publica-
tions on vitamin D in the three most important Swiss med-
ical journals of the French speaking part of Switzerland.
We searched for publications with the word "vitamin D"
in Swiss Medical Weekly, Swiss Medical Forum and La
Revue Médicale de la Suisse Romande.
Statistical analysis
We tested for normal distribution of the results by Shapiro-
Wilk and Shapiro-Francia tests for normality. All results
were normally distributed. To compare proportions, we
performed a Chi square test. To compare vitamin D level
between the two unpaired samples, we performed a t-test
for unpaired measurement. A p-value <0.05 was con-
sidered significant.
Results
A total of 336 patients were screened in 2011. We excluded
37 patients who received a high dose of vitamin D in the six
Figure 1
Mean 25-OH vitamin D (in ng/ml) in 2009 and 2011, p = 0.0001
Figure 2
Effects of vitamin D3 supplementation: X-axis: 3 groups: all
patients, nonsupplemented patients and patients with daily
supplement of vitamin D3; Y-axis: percentage of patients with
deficiency, insufficiency or normal results (1 = 100%); * and #:
comparison between 2009 and 2011, the number of patients with
normal results being significantly higher in 2011
months preceding the study and 60 patients who were not
regularly followed up in our clinic between 2009 and 2011.
We then analysed the results of the 239 remaining patients,
compared with 230 patients in 2009 using the same exclu-
sion criteria.
In 2011, 173 patients had inflammatory rheumatic disease
(essentially rheumatoid arthritis or spondylarthropathy), 65
had osteoporosis and 26 had degenerative disease com-
pared with 200, 33 and 23 patients, respectively, in 2009
(nonexclusive categories).
As far as body mass index (BMI) and sex were concerned,
there was no significant difference between the two pop-
ulations: BMI was 26.2 kg/m2 in 2009 versus 26.5 kg/m2
in 2011 and 70% of patients were women in 2009 and in
2011. Nevertheless, the population was significantly older
in 2011 (age 51.9 vs 55.9 year old, p <0.01). Only 48 pa-
tients (20%) were the same in 2009 and 2011.
Mean vitamin D levels in 2009 and 2011 are summarised
in table 1. In 2011, it was 23.8 ng/ml, range 4–53 ng/ml
(20.8 ng/ml in 2009, p = 0.0001, fig. 1). Nine patients (4%)
had vitamin D deficiency (18 [8%] in 2009), 163 patients
(68%) had insufficiency (181 [79%] in 2009) and 66 pa-
tients (28%) had normal results (31 [13%] in 2009). Ninety
patients (38%) were on daily oral supplementation of vit-
amin D (38% in 2009). One (1%) of them had a defi-
ciency (4/88 [5%] in 2009), 43 (48%) insufficiency (62/
88 [70%] in 2009) and 46 (51%) had normal results (22/
88 [25%] in 2009). A total of 149 patients were not receiv-
ing any supplementation: 8 (5%) had deficiency (14/142
[10%] in 2009), 121 (81%) insufficiency (119/142 [83%]
in 2009) and 20 [13%] normal vitamin D level (9/142 [6%]
in 2009). Compared with 2009, significantly more patients
had normal results in 2011, both those on oral daily sup-
plementation (p <0.01) and those without any supplement-
ation (p = 0.04) (fig. 2).
If we used 20 ng/ml as a cut-off (rather than 30 ng/ml),
52% patients had levels >20 ng/ml in 2009 and 66% in
2011 and the difference was statistically significant (p =
0.001).
During the years separating the two study periods the num-
ber of 25-OH vitamin D dosages (3,056 in 2008 and 6,896
in 2011) and the prescription of high doses of vitamin D3
(660 in 2008 and 2,530 in 2011) increased in our hospital
(fig. 3). In the general outpatient clinic of the same hospit-
al the prescription of high doses of vitamin D3 increased
by more than 300% between 2008 and 2011. On the other
hand in the same clinic, the prescription of daily supple-
ments increased only of 40%.
In addition the number of publications about vitamin D had
increased between 2008 and 2011. Specifically, the number
of publications with the phrase “vitamin D” in Swiss Med-
ical Weekly, Swiss Medical Forum and Revue Médicale
Suisse increased from four to nineteen.
Discussion
Prevalence of hypovitaminosis D decreased in two years
from 86% to 72% (or from 48% to 34% using the cut-off
of 20 ng/ml) despite the fact that the population was older
in 2011. These results were mainly due to the higher num-
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ber of normal 25-OH vitamin D levels observed in patients
taking oral daily vitamin D (increasing from 25% to 51%).
This was not explained by a higher prescription of daily vit-
amin D supplement (38% in both years). In addition, this
could not be related to a difference in sun exposure since
the average of sunshine in the region was globally high-
er in summer 2009 compared to summer 2011. (Internet:
http://www.meteoschweiz.admin.ch/web/fr/climat/). It was
probably related with better adherence to daily oral supple-
ments by the supplemented patients.
It could also be minimally related to the higher percentage
of patients with osteoporosis in 2011, since they are pos-
sibly more motivated than the patients with inflammatory
rheumatic or degenerative disease to take their supplements
regularly.
We also think this might be due to better information and
awareness of the physicians about hypovitaminosis D who
probably asked more regularly about vitamin D supple-
mentation adherence and helped themselves and the pa-
tients with more systematic 25-OH vitamin D level meas-
urements.
It could also be related to higher prescription of high doses
of vitamin D3 supplement in the previous years in our de-
partment particularly in the nonsupplemented patients. Of
note, this kind of supplementation has been shown to be ef-
ficient in selected cases despite some controversy concern-
ing its safety [15].
Figure 3
Evolution of vitamin D dosages and prescriptions between 2008
and 2011 in Lausanne University Hospital
It is also reasonable to think that patients not receiving reg-
ular prescriptions for vitamin D were simply more aware of
the problem of hypovitaminosis D and took more regular
natural supplement, in food for example.
Our study has many limitations. Firstly, it is an uncon-
trolled study. Secondly, the two populations compared are
different. Thirdly, we did not perform a specific verifica-
tion of compliance with daily vitamin D supplementation.
Finally we could not determine precisely which patients
benefited from prescription of high doses of vitamin D3
between December 2009 and April 2011 (incomplete files).
Therefore we cannot demonstrate the proposed relation
between the increase in adherence with daily supplement
and the prescription of high doses of vitamin D and the bet-
ter results in 2011.
Our study has nevertheless some strengths. Interestingly
we could show a significant increase in vitamin D levels
despite the older age and decreased sun exposure. Most
importantly it is a true population-based study and the
two populations are very similar. We used the same dosage
method and we did the blood tests at the same time of the
year (same month) at the same policlinic (same place). And
finally it gives a simple and strong message about the pos-
sibility of improving the vitamin D status in a population
with better physician information and patient education.
It is indeed very important to improve our capacity to sup-
plement a rheumatology population considering the well-
known relationship between hypovitaminosis D and mus-
culoskeletal health and the increasing evidences of a cor-
relation between the activity of autoimmune rheumatic dis-
ease and vitamin D status [16–18].
In conclusion, the prevalence of low vitamin D decreased
in two years from 86% to 72%. These results were mainly
due to the higher number of normal 25-OH vitamin D
levels observed in patients taking oral daily vitamin D (in-
creasing from 25% to 51%). These results may be ex-
plained by: 1) better adherence to oral daily vitamin D in
the supplemented patients; 2) better information of physi-
cians about hypovitaminosis D; 3) more frequent screening
of vitamin D level and 4) higher prescription of high doses
of vitamin D if this is deemed needed.
Table 1: Patients’ characteristics in 2009 and 2011.
2011 2009
All Number of patients 239 (167 women) 230 (162 women)
25-OH Vitamin D (ng/ml) 23.8 20.8
Daily vitamin D3 supplement 38% 38%
Age (years) 56 52
Deficiency Number of patients 9 18
25-OH Vitamin D (ng/ml) 6.6 8.2
Daily vitamin D3 supplement 11% 22%
Age (years) 53 50
Insufficiency Number of patients 164 181
25-OH Vitamin D (ng/ml) 20.3 19.5
Daily vitamin D3 supplement 26% 34%
Age (years) 54 52
Normal Number of patients 66 31
25-OH Vitamin D (ng/ml) 34.9 35.6
Daily vitamin D3 supplement 70% 71%
Age (years) 62 54
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Figures (large format)
Figure 1
Mean 25-OH vitamin D (in ng/ml) in 2009 and 2011, p = 0.0001
Figure 2
Effects of vitamin D3 supplementation: X-axis: 3 groups: all patients, nonsupplemented patients and patients with daily supplement of vitamin
D3; Y-axis: percentage of patients with deficiency, insufficiency or normal results (1 = 100%); * and #: comparison between 2009 and 2011, the
number of patients with normal results being significantly higher in 2011
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Figure 3
Evolution of vitamin D dosages and prescriptions between 2008 and 2011 in Lausanne University Hospital
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